LEADER 03567nam  22006855  450 
001 9910300185703321
005 20200703023513.0
010   $a3-319-09555-2
024 7 $a10.1007/978-3-319-09555-4
035   $a(CKB)3710000000291431
035   $a(EBL)1966916
035   $a(OCoLC)908086367
035   $a(SSID)ssj0001386678
035   $a(PQKBManifestationID)11814667
035   $a(PQKBTitleCode)TC0001386678
035   $a(PQKBWorkID)11374542
035   $a(PQKB)11009540
035   $a(DE-He213)978-3-319-09555-4
035   $a(MiAaPQ)EBC1966916
035   $a(PPN)183092635
035   $a(EXLCZ)993710000000291431
100   $a20141118d2015      u|         0
101 0 $aeng
135   $aur|n|---|||||
181   $ctxt
182   $cc
183   $acr
200 10$aPharmacotherapy in Aortic Disease /$fedited by Arturo Evangelista, Christoph A. Nienaber
205   $a1st ed. 2015.
210  1$aCham :$cSpringer International Publishing :$cImprint: Springer,$d2015.
215   $a1 online resource (281 p.)
225 1 $aCurrent Cardiovascular Therapy ;$v7
300   $aDescription based upon print version of record.
311   $a3-319-09554-4 
320   $aIncludes bibliographical references and index.
327   $aAortic atherosclerosis as an embolic source -- Aortitis -- Aortic aneurysm -- Marfan Syndrome -- Acute Aortic Syndrome -- Chronic aortic dissection.
330   $aThis book is driven by the considerable progress made by novel imaging techniques in understanding the pathophysiology and evolution of aortic disease and its diagnosis. Despite the lack of symptoms in stable conditions, most aortic diseases have a high morbidity and mortality. New therapeutic strategies such as endovascular treatment and surgical techniques have appeared to improve conventional surgery in advanced phases of the disease, but until recently, medical treatment has focused on the control of cardiovascular risk factors using beta-blockers to reduce aortic wall stress by reducing blood pressure and heart rate. Pharmacotherapy in Aortic Disease updates the reader on the new medical treatment that are changing the natural history of these diseases. Leading experts have created a critical in-depth, yet concise, analysis of the available medical treatments for different aortic disease entities. Both basic research studies and clinical trials discussed in this book serve as a base for improving therapeutic management, delaying the need for surgery, and prolonging survival in these patients.
410  0$aCurrent Cardiovascular Therapy ;$v7
606   $aCardiology
606   $aChemotherapy
606   $aHeart$xSurgery
606   $aCardiology$3https://scigraph.springernature.com/ontologies/product-market-codes/H33037
606   $aPharmacotherapy$3https://scigraph.springernature.com/ontologies/product-market-codes/H69000
606   $aCardiac Surgery$3https://scigraph.springernature.com/ontologies/product-market-codes/H59028
615  0$aCardiology.
615  0$aChemotherapy.
615  0$aHeart$xSurgery.
615 14$aCardiology.
615 24$aPharmacotherapy.
615 24$aCardiac Surgery.
676   $a610
676   $a615.1
676   $a616.12
676   $a617412
702   $aEvangelista$b Arturo$4edt$4http://id.loc.gov/vocabulary/relators/edt
702   $aNienaber$b Christoph A$4edt$4http://id.loc.gov/vocabulary/relators/edt
906   $aBOOK
912   $a9910300185703321
996   $aPharmacotherapy in Aortic Disease$91831116
997   $aUNINA